Inflammation and ovarian cancer-current views

Ginekologia Polska

Volumn 84, Issue 4, 2013, Pages 293-297

  Kisielewski, Rafał ^a   Tołwińska, Agnieszka ^b   Mazurek, Andrzej ^a   Laudański, Piotr ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Niepubliczny Zak ad Opieki Zdrowotnej EDMED   (Poland)

Author keywords

Carcinogenesis; Endometriosis; Fallopian tube cancer; Inflammation; Ovarian cancer

Indexed keywords

EID: 84879231946     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: 10.17772/gp/1579     Document Type: Article

References (29)

1. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 2006, 20, 207-225.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010, 60, 277-300.
3. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010, 177, 1053-1064.
4. Fathalla M. Incessant ovulation--a factor in ovarian neoplasia?. Lancet. 1971, 2, 163.
5. Cramer D, Welch W. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst. 1983, 71, 717-721.
6. Altinoz M, Korkmaz R. NF-kappaB, macrophage migration inhibitory factor and cyclooxygenaseinhibitions as likely mechanisms behind the acetaminophen- and NSAID-prevention of the ovarian cancer. Neoplasma. 2004, 51, 239-247.
7. Freedman R, Deavers M, Liu J, Wang E. Peritoneal inflammation - A microenvironment for Epithelial Ovarian Cancer (EOC). J Transl Med. 2004, 2, 23.
8. Ness R, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999, 91, 1459-1467.
9. McSorley M, Alberg A, Allen D, [et al.]. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol. 2007, 109, 933-941.
10. Calzado M, Bacher S, Schmitz M. NF-kappaB inhibitors for the treatment of inflammatory diseases and cancer. Curr Med Chem. 2007, 14, 367-376.
11. Callahan M, Crum C, Medeiros F, [et al.]. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007, 25, 3985-3990.
12. Synowiec A, Wcislo G, Bodnar L, Szczylik C. [Surgical treatment in ovarian cancer prevention in carriers of the BRCA1/BRCA2 mutation]. Ginekol Pol. 2012, 83, 51-56. Polish.
13. Medeiros F, Muto M, Lee Y, [et al.]. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006, 30, 230-236.
14. Nunobe S, Nakanishi Y, Taniguchi H, [et al.]. Two distinct pathways of tumorigenesis of adenocarcinomas of the esophagogastric junction, related or unrelated to intestinal metaplasia. Pathol Int. 2007, 57, 315-321.
15. Soper D, Brockwell N, Dalton H, Johnson D. Observations concerning the microbial etiology of acute salpingitis. Am J Obstet Gynecol. 1994, 170, 1008-1014, discussion 1014-1017.
16. Lin H, Tu Y, Lin S, [et al.]. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol. 2011, 12, 900-904.
17. Huncharek M, Muscat J. Perineal talc use and ovarian cancer risk: a case study of scientific standards in environmental epidemiology. Eur J Cancer Prev. 2011, 20, 501-507.
18. Liu D, Hitchcock A. Endometriosis: its association with retrograde menstruation, dysmenorrhoea and tubal pathology. Br J Obstet Gynaecol. 1986, 93, 859-862.
19. Seidman J, Sherman M, Bell K, [et al.]. Salpingitis, salpingoliths, and serous tumors of the ovaries: is there a connection?. Int J Gynecol Pathol. 2002, 21, 101-107.
20. Post P, Casparie M, Blaauwgeers J, de Blok S. Reduced risk of ovarian cancer after hysterectomy. Acta Obstet Gynecol Scand. 2005, 84, 1024, author reply 1024-1025.
21. Ness R, Modugno F. Endometriosis as a model for inflammation-hormone interactions in ovarian and breast cancers. Eur J Cancer. 2006, 42, 691-703.
22. Missmer S, Hankinson S, Spiegelman D, [et al.]. Reproductive history and endometriosis among premenopausal women. Obstet Gynecol. 2004, 104, 965-974.
23. Wei J, William J, Bulun S. Endometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects. Int J Gynecol Pathol. 2011, 30, 553-568.
24. Laudanski P, Szamatowicz J, Ramel P. Matrix metalloproteinase-13 and membrane type-1 matrix metalloproteinase in peritoneal fluid of women with endometriosis. Gynecol Endocrinol. 2005, 21, 106-110.
25. Szamatowicz J, Laudanski P, Tomaszewska I, Szamatowicz M. Chemokine growth-regulatedalpha: a possible role in the pathogenesis of endometriosis. Gynecol Endocrinol. 2002, 16, 137-141.
26. Laudanski P, Szamatowicz J, Kowalczuk O, [et al.]. Expression of selected tumor suppressor and oncogenes in endometrium of women with endometriosis. Hum Reprod. 2009, 24, 1880-1890.
27. Laudański P, Kowalczuk O, Klasa-Mazurkiewicz D, [et al.]. Selective gene expression profiling of mTOR-associated tumor suppressor and oncogenes in ovarian cancer. Folia Histochem Cytobiol. 2011, 49, 317-324.
28. Yagyu T, Tsuji Y, Haruta S, [et al.]. Activation of mammalian target of rapamycin in postmenopausal ovarian endometriosis. Int J Gynecol Cancer. 2006, 16, 1545-1551.
29. Leconte M, Nicco C, Ngô C, [et al.]. The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice. Am J Pathol. 2011, 179, 880-889.